Gubra (GUBRA) Investor presentation summary

Strategic positioning and business model

• Operates as a disease-agnostic techbio with deep peptide and preclinical expertise, structured into Biotech, CRO, and Ventures units for integrated value creation.

• Biotech drives R&D and pipeline strategy, CRO provides foundational revenue, and Ventures accelerates value through external capital and new company creation.

• Shared scientific core enables faster pipeline progression, broader portfolio, and multiple monetization paths.

Pipeline and clinical progress

• Early clinical pipeline includes multiple obesity-focused assets, with several expected to enter Phase 2 in 2026.

• ABBV-295 (amylin analog) and BI 3034701 (triple agonist) are out-licensed and advancing to Phase 2, showing strong weight loss and safety profiles.

• GUB-UCN2, an internal program, targets muscle preservation and is set for Phase 1/2a trial in H2 2026.

Innovation and technology platforms

• AI-driven StreamLine platform enables rapid peptide discovery, delivering multiple assets with high novelty and patentability.

• Focus on muscle-preserving therapies and combination treatments aligns with shifting obesity treatment paradigms.

• Advanced 3D imaging and AI quantification support preclinical validation and muscle growth analysis.